Cyclic fasting bolsters cholesterol biosynthesis inhibitors’ anticancer activity
Open Access
- 31 October 2023
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-16
Abstract
Identifying oncological applications for drugs that are already approved for other medical indications is considered a possible solution for the increasing costs of cancer treatment. Under the hypothesis that nutritional stress through fasting might enhance the antitumour properties of at least some non-oncological agents, by screening drug libraries, we find that cholesterol biosynthesis inhibitors (CBIs), including simvastatin, have increased activity against cancers of different histology under fasting conditions. We show fasting’s ability to increase CBIs’ antitumour effects to depend on the reduction in circulating insulin, insulin-like growth factor-1 and leptin, which blunts the expression of enzymes from the cholesterol biosynthesis pathway and enhances cholesterol efflux from cancer cells. Ultimately, low cholesterol levels through combined fasting and CBIs reduce AKT and STAT3 activity, oxidative phosphorylation and energy stores in the tumour. Our results support further studies of CBIs in combination with fasting-based dietary regimens in cancer treatment and highlight the value of fasting for drug repurposing in oncology.Keywords
This publication has 73 references indexed in Scilit:
- PAPP-A negatively regulates ABCA1, ABCG1 and SR-B1 expression by inhibiting LXRα through the IGF-I-mediated signaling pathwayAtherosclerosis, 2012
- Fasting Cycles Retard Growth of Tumors and Sensitize a Range of Cancer Cell Types to ChemotherapyScience Translational Medicine, 2012
- Methyl‐beta‐cyclodextrin induces mitochondrial cholesterol depletion and alters the mitochondrial structure and bioenergeticsFEBS Letters, 2010
- Catastrophic NAD+ Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAEPLOS ONE, 2009
- Leptin modulates ACAT1 expression and cholesterol efflux from human macrophagesAmerican Journal of Physiology-Endocrinology and Metabolism, 2009
- The High-Mobility Group A1a/Signal Transducer and Activator of Transcription-3 Axis: An Achilles Heel for Hematopoietic Malignancies?Cancer Research, 2008
- Drug repositioning: identifying and developing new uses for existing drugsNature Reviews Drug Discovery, 2004
- Influence of insulin on cholesterol removal from macrophages and cholesterol ester uptake by HepG2 cellsEuropean Journal of Clinical Investigation, 1996
- Establishment of six human pancreatic cancer cell lines and their sensitivities to anti-tumor drugs.The Tohoku Journal of Experimental Medicine, 1986
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976